International Journal of General Medicine (Nov 2021)

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients

  • Albaker W,
  • Al Sheikh M,
  • Albakr A,
  • Alkhafaji D,
  • Al Besher E,
  • Al-Hariri M

Journal volume & issue
Vol. Volume 14
pp. 8643 – 8650

Abstract

Read online

Waleed Albaker,1 Mona Al Sheikh,2 Aishah Albakr,3 Dania Alkhafaji,1 Eman Al Besher,4 Mohammed Al-Hariri2 1Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 2Department of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 3Department of Neurology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 4Department of Family Medicine, Ministry of Health, Dammam, Saudi ArabiaCorrespondence: Mohammed Al-HaririDepartment of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, P.O. Box 2114-31451, Dammam, Saudi ArabiaTel +966 50-727-5028Email [email protected]: Unmanaged cases of obesity might lead to serious conditions and complications, which impair patients’ lives. The aim of this study was to assess the effectiveness and safety of daily 3 mg subcutaneous (s/c) Liraglutide amongst obese non-diabetic patients in Eastern Province, Saudi Arabia.Methods: A retrospective cohort study of obese non-diabetic Saudi patients with obesity managed with s/c Liraglutide 3.0 mg who visited the outpatient clinic in Al Mashfa Hospital, Al Khobar, KSA during 2019– 2021. We collected patient data from the electronic reporting system for different parameters. Body weight, hemoglobin A1c %, systolic and diastolic blood pressure mmHg were obtained at baseline and after the intervention.Results: Records of 258 patients who were using a daily dose of Liraglutide 3.0 mg s/c for at least four months have been reviewed. The body weight loss of patients who used Liraglutide for four months was 8.1± 0.8 kg. Moreover, around 204 patients continued for up to six months. Meanwhile, the mean body weight loss was 13 kg. There was a significant reduction of hemoglobin A1c (HbA1c) % by 0.43%. The majority of patients (94.5%) reported satisfaction with the treatment, while adverse events were mainly nausea, vomiting and constipation.Conclusion: Daily s/c Liraglutide of 3.0 mg is effective in producing significant body weight reduction in obese non-diabetic Saudi patients with tolerable minimal side effects and may provide health benefits in terms of reduced risk of obesity and its related outcomes.Keywords: obesity, Liraglutide, weight loss, Saudi

Keywords